Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Naftidrofuryl

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Naftidrofuryl
Clinical data
Trade namesPraxilene
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Eliminationhalf-life1 - 3.5 hours
Identifiers
  • (RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.045.960Edit this at Wikidata
Chemical and physical data
FormulaC24H33NO3
Molar mass383.532 g·mol−1
3D model (JSmol)
  • O=C(OCCN(CC)CC)C(Cc2c1ccccc1ccc2)CC3OCCC3
  • InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3 checkY
  • Key:KBAFPSLPKGSANY-UHFFFAOYSA-N checkY
  (verify)

Naftidrofuryl (INN), also known asnafronyl or as theoxalate saltnaftidrofuryl oxalate ornafronyl oxalate, is avasodilator used in the management of peripheral andcerebralvascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selectiveantagonist of5-HT2 receptors (with action as aninverse agonist of the5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment ofintermittent claudication due toperipheral arterial disease.

Naftidrofuryl is marketed under a variety oftrade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat suddenidiopathic hearing loss and acutetinnitus.[4]

Naftidrofuryl may be effective for relieving the pain of musclecramps.[5]

Adverse effects

[edit]

Naftidrofuryl has been associated withnausea,abdominal pain andrash. Rarely,hepatitis andliver failure have been reported.[6]

See also

[edit]

References

[edit]
  1. ^Lanzer P, Topol EJ (20 December 2013).Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–.ISBN 978-3-642-56225-9.
  2. ^Morton IK, Hall JM (6 December 2012).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–.ISBN 978-94-011-4439-1.
  3. ^Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T (August 2009)."Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate".Journal of Pharmacological Sciences.110 (4):445–50.doi:10.1254/jphs.09124FP.PMID 19672037.
  4. ^"DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten".www.der-arzneimittelbrief.de. Archived fromthe original on 2018-09-20. Retrieved2018-12-13.
  5. ^Katzberg HD, Khan AH, So YT (February 2010)."Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology".Neurology.74 (8):691–6.doi:10.1212/WNL.0b013e3181d0ccca.PMID 20177124.
  6. ^Brayfield A, ed. (14 January 2014)."Naftidrofuryl Oxalate".Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved6 August 2014.
Phenylethanolamine derivatives
Alpha blockers
Nicotinic acid and derivatives
Purine derivatives
Ergot alkaloids
Other peripheral vasodilators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Naftidrofuryl&oldid=1321597737"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp